MCUJF Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 19:27):

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States...

Stats
Dzisiejszy wolumen	2 800.00
Średni wolumen	1 274.00
Kapitalizacja rynkowa	7.72M
EPS	$0 ( 2024-04-04 )
Następna data zysków	( $0 ) 2024-05-24
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-10.57
ATR14	$0 (0.00%)

Medicure Inc. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Medicure Inc. Finanse

Annual	2023
Przychody:	$21.69M
Zysk brutto:	$13.56M (62.48 %)
EPS:	$-0.0883

FY	2023
Przychody:	$21.69M
Zysk brutto:	$13.56M (62.48 %)
EPS:	$-0.0883

FY	2022
Przychody:	$23.07M
Zysk brutto:	$16.08M (69.69 %)
EPS:	$0.130

FY	2021
Przychody:	$21.74M
Zysk brutto:	$12.71M (58.46 %)
EPS:	$-0.0700

Financial Reports:

No articles found.

Medicure Inc.

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers ReDS, a non-invasive medical device that offers measurement of lung fluid for the management of congestive heart failure. Further, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail pharmacies, as well as online. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.